Doximity
DOCSNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $32.42 Prior regular-session close from the quote source.
- $31.96–$33.63 Regular-session low and high so far today.
- 2.3M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 4 projected Projected for 2027-02-04 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $17.15–$53.46 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own DOCS if Doximity is a high-margin physician network whose stock depends on pharma and health-system customers continuing to treat its verified clinician audience as a must-buy channel, not just another ad platform.
DOCS price history
Loading recent earnings…
Investment thesis
What must happen next
Doximity’s verified physician network remains a scarce distribution channel for healthcare marketers, so customer demand continues to shift toward the platform rather than generic digital advertising.StrengtheningMateriality: High
Item 1 profile description identifies Doximity as a leading physician-first tech company with over 3 million registered members as of March 31, 2026. If this holds, revenue growth is driven by a durable network advantage; if it breaks, Doximity becomes a less differentiated ad vendor.
Watch: Large pharma marketers move HCP engagement budgets to Veeva, IQVIA, Medscape/Sermo, or in-house CRM/data platforms because those alternatives prove better ROI.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 profile description identifies Doximity as a leading physician-first tech company with over 3 million registered members as of.
Open source ↗The platform’s first-party physician audience and software-like delivery model preserve premium unit economics instead of requiring labor-heavy services or paid traffic to sustain growth.StrengtheningMateriality: High
GAAP annual gross profit was $574.5 million on $644.9 million of revenue in FY2026, implying a gross margin of about 89%. High gross margins are the proof that Doximity’s network creates pricing power; margin compression would signal that growth is becoming more costly or less differentiated.
Watch: Doximity must buy more traffic, data, content, or third-party technology to maintain physician engagement.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $574.5 million on $644.9 million of revenue in FY2026, implying a gross margin of about.
Open source ↗Doximity’s small, specialized employee base and platform economics should let it reinvest in products while still converting incremental revenue into operating income, but FY2026 shows this discipline is not automatic.HoldingMateriality: Medium
GAAP annual operating income increased from $125.1 million in FY2023 to $214.9 million in FY2026. The stock needs profitable growth, not just growth; if operating leverage fails, the premium-quality thesis weakens.
Watch: AI, clinical workflow, or sales investments require sustained hiring and infrastructure spending without clear monetization.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income increased from $125.1 million in FY2023 to $214.9 million in FY2026.
Open source ↗Doximity’s asset-light model and customer economics continue to turn accounting profit into cash that can fund product investment and capital returns without balance-sheet stress.StrengtheningMateriality: Medium
GAAP annual operating cash flow rose from $179.6 million in FY2023 to $326.5 million in FY2026. Strong cash conversion gives shareholders resilience and optionality; deterioration would suggest weaker collections, lower quality earnings, or more capital-intensive growth.
Watch: Pharma budget delays or tougher customer payment terms stretch receivables and reduce cash conversion.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow rose from $179.6 million in FY2023 to $326.5 million in FY2026.
Open source ↗Management must convert the network’s growth into per-share earnings rather than allowing reinvestment, stock compensation, taxes, or capital allocation to absorb the economics.HoldingMateriality: Medium
GAAP diluted EPS increased from $0.53 in FY2023 to $0.98 in FY2026. Owners are paid in per-share value; if EPS does not compound despite revenue growth, the business may be better than the stock.
Watch: Stock-based compensation or hiring rises faster than the value created by new products.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP diluted EPS increased from $0.53 in FY2023 to $0.98 in FY2026.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Doximity’s verified physician network remains a scarce distribution channel for healthcare marketers, so customer demand continues to shift toward the platform rather than generic digital advertising. If this holds, revenue growth is driven by a durable network advantage; if it breaks, Doximity becomes a less differentiated ad vendor.
The platform’s first-party physician audience and software-like delivery model preserve premium unit economics instead of requiring labor-heavy services or paid traffic to sustain growth. High gross margins are the proof that Doximity’s network creates pricing power; margin compression would signal that growth is becoming more costly or less differentiated.
Doximity’s small, specialized employee base and platform economics should let it reinvest in products while still converting incremental revenue into operating income, but FY2026 shows this discipline is not automatic. The stock needs profitable growth, not just growth; if operating leverage fails, the premium-quality thesis weakens.
Doximity’s asset-light model and customer economics continue to turn accounting profit into cash that can fund product investment and capital returns without balance-sheet stress. Strong cash conversion gives shareholders resilience and optionality; deterioration would suggest weaker collections, lower quality earnings, or more capital-intensive growth.
Management must convert the network’s growth into per-share earnings rather than allowing reinvestment, stock compensation, taxes, or capital allocation to absorb the economics. Owners are paid in per-share value; if EPS does not compound despite revenue growth, the business may be better than the stock.
All standing thesis claims
Original report summary
Doximity is a high-margin physician network whose stock depends on pharma and health-system customers continuing to treat its verified clinician audience as a must-buy channel, not just another ad platform.
Bull case and bear case
Bull case and bear case for Doximity
Where the evidence on Doximity stands: Holding on the latest evidence (Nov 7, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Doximity’s verified physician network remains a scarce distribution channel for healthcare marketers, so customer demand continues to shift toward the platform rather than generic digital advertising.
The platform’s first-party physician audience and software-like delivery model preserve premium unit economics instead of requiring labor-heavy services or paid traffic to sustain growth.
Doximity’s small, specialized employee base and platform economics should let it reinvest in products while still converting incremental revenue into operating income, but FY2026 shows this discipline is not automatic.
Doximity’s asset-light model and customer economics continue to turn accounting profit into cash that can fund product investment and capital returns without balance-sheet stress.
Management must convert the network’s growth into per-share earnings rather than allowing reinvestment, stock compensation, taxes, or capital allocation to absorb the economics.
Bear case: what would count against it
Large pharma marketers move HCP engagement budgets to Veeva, IQVIA, Medscape/Sermo, or in-house CRM/data platforms because those alternatives prove better ROI.
Doximity must buy more traffic, data, content, or third-party technology to maintain physician engagement.
AI, clinical workflow, or sales investments require sustained hiring and infrastructure spending without clear monetization.
Thesis-Break Engine
What has broken in Doximity’s thesis
Each break OptimistFi flagged on Doximity, dated — with what has historically followed the same kind of break across the market, not a forecast for Doximity.
- Price target fell below the stockcondition set before this filing
Across all companies, this kind of break has happened 1,809 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Doximity’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Doximity filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Doximity filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Doximity filed an SEC 8-K on 2026-05-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large pharma marketers move HCP engagement budgets to Veeva, IQVIA, Medscape/Sermo, or in-house CRM/data platforms because those alternatives prove better ROI.
- Doximity must buy more traffic, data, content, or third-party technology to maintain physician engagement.
- AI, clinical workflow, or sales investments require sustained hiring and infrastructure spending without clear monetization.
- Pharma budget delays or tougher customer payment terms stretch receivables and reduce cash conversion.
- Stock-based compensation or hiring rises faster than the value created by new products.
DOCS news
Loading headlines…
Financial statements
DOCS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
DOCS: quick answers
- When does Doximity (DOCS) report earnings next?
- Doximity's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is DOCS's short interest?
- As of October 30, 2026, 6.9M DOCS shares were sold short, 5.45% of its shares outstanding, down 23.5% from the count before. At the stock's average daily volume that is 2.7 days to cover. FINRA publishes the count twice a month. DOCS short interest history
- Have members of Congress traded DOCS?
- 9 trades in DOCS have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed DOCS trade
- Which well-known investors own DOCS?
- 2 of the 37 well-known funds tracked here reported DOCS shares in their latest 13F filings. By share of the fund's portfolio: Fundsmith (Terry Smith), 0.1%; Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios
DOCS in well-known investors’ portfolios
2 of 37 funds reported DOCS shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Terry SmithFundsmith | 0.10% | $13.5M | −5.6% | Q2 2026 |
| Ray DalioBridgewater Associates | 0.01% | $2.7M | +9.5% | Q2 2026 |
